256 related articles for article (PubMed ID: 24212974)
1. Emerging cancer vaccines: the promise of genetic vectors.
Aurisicchio L; Ciliberto G
Cancers (Basel); 2011 Sep; 3(3):3687-713. PubMed ID: 24212974
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and therapeutic efficacy of a dual-component genetic cancer vaccine cotargeting carcinoembryonic antigen and HER2/neu in preclinical models.
Aurisicchio L; Peruzzi D; Koo G; Wei WZ; La Monica N; Ciliberto G
Hum Gene Ther; 2014 Feb; 25(2):121-31. PubMed ID: 24195644
[TBL] [Abstract][Full Text] [Related]
3. Heterologous prime-boost immunization co-targeting dual antigens inhibit tumor growth and relapse.
Guo Q; Wang L; Xu P; Geng F; Guo J; Dong L; Bao X; Zhou Y; Feng M; Wu J; Wu H; Yu B; Zhang H; Yu X; Kong W
Oncoimmunology; 2020 Nov; 9(1):1841392. PubMed ID: 33224629
[TBL] [Abstract][Full Text] [Related]
4. Genetic cancer vaccines: current status and perspectives.
Aurisicchio L; Ciliberto G
Expert Opin Biol Ther; 2012 Aug; 12(8):1043-58. PubMed ID: 22577875
[TBL] [Abstract][Full Text] [Related]
5. A Plasmodium vivax Plasmid DNA- and Adenovirus-Vectored Malaria Vaccine Encoding Blood-Stage Antigens AMA1 and MSP1
Obaldia N; Stockelman MG; Otero W; Cockrill JA; Ganeshan H; Abot EN; Zhang J; Limbach K; Charoenvit Y; Doolan DL; Tang DC; Richie TL
Clin Vaccine Immunol; 2017 Apr; 24(4):. PubMed ID: 28179404
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity when utilizing adenovirus serotype 4 and 5 vaccines expressing circumsporozoite protein in naïve and adenovirus (Ad5) immune mice.
Schuldt NJ; Aldhamen YA; Godbehere-Roosa S; Seregin SS; Kousa YA; Amalfitano A
Malar J; 2012 Jun; 11():209. PubMed ID: 22720732
[TBL] [Abstract][Full Text] [Related]
7. In vivo electroporation in DNA-VLP prime-boost preferentially enhances HIV-1 envelope-specific IgG2a, neutralizing antibody and CD8 T cell responses.
Huang X; Zhu Q; Huang X; Yang L; Song Y; Zhu P; Zhou P
Vaccine; 2017 Apr; 35(16):2042-2051. PubMed ID: 28318765
[TBL] [Abstract][Full Text] [Related]
8. Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors.
Diaz CM; Chiappori A; Aurisicchio L; Bagchi A; Clark J; Dubey S; Fridman A; Fabregas JC; Marshall J; Scarselli E; La Monica N; Ciliberto G; Montero AJ
J Transl Med; 2013 Mar; 11():62. PubMed ID: 23497415
[TBL] [Abstract][Full Text] [Related]
9. DNA vaccines, electroporation and their applications in cancer treatment.
Lee SH; Danishmalik SN; Sin JI
Hum Vaccin Immunother; 2015; 11(8):1889-900. PubMed ID: 25984993
[TBL] [Abstract][Full Text] [Related]
10. Heterologous prime-boost vaccination against tuberculosis with recombinant Sendai virus and DNA vaccines.
Hu Z; Jiang W; Gu L; Qiao D; Shu T; Lowrie DB; Lu SH; Fan XY
J Mol Med (Berl); 2019 Dec; 97(12):1685-1694. PubMed ID: 31786669
[TBL] [Abstract][Full Text] [Related]
11. Enhanced immunogenicity and antitumour effects with heterologous prime-boost regime using vaccines based on MG7-Ag mimotope of gastric cancer.
Lin T; Liang S; Meng F; Han Q; Guo C; Sun L; Chen Y; Liu Z; Yu Z; Xie H; Ding J; Fan D
Clin Exp Immunol; 2006 May; 144(2):319-25. PubMed ID: 16634806
[TBL] [Abstract][Full Text] [Related]
12. Positive immunomodulatory effects of heterologous DNA vaccine- modified live vaccine, prime-boost immunization, against the highly-pathogenic PRRSV infection.
Sirisereewan C; Nedumpun T; Kesdangsakonwut S; Woonwong Y; Kedkovid R; Arunorat J; Thanawongnuwech R; Suradhat S
Vet Immunol Immunopathol; 2017 Jan; 183():7-15. PubMed ID: 28063479
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity.
Lemckert AA; Sumida SM; Holterman L; Vogels R; Truitt DM; Lynch DM; Nanda A; Ewald BA; Gorgone DA; Lifton MA; Goudsmit J; Havenga MJ; Barouch DH
J Virol; 2005 Aug; 79(15):9694-701. PubMed ID: 16014931
[TBL] [Abstract][Full Text] [Related]
14. Electroporation as a "prime/boost" strategy for naked DNA vaccination against a tumor antigen.
Buchan S; Grønevik E; Mathiesen I; King CA; Stevenson FK; Rice J
J Immunol; 2005 May; 174(10):6292-8. PubMed ID: 15879128
[TBL] [Abstract][Full Text] [Related]
15. Enhancing Th2 immune responses against amyloid protein by a DNA prime-adenovirus boost regimen for Alzheimer's disease.
Kim HD; Jin JJ; Maxwell JA; Fukuchi K
Immunol Lett; 2007 Sep; 112(1):30-8. PubMed ID: 17686533
[TBL] [Abstract][Full Text] [Related]
16. Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens.
Asbach B; Kliche A; Köstler J; Perdiguero B; Esteban M; Jacobs BL; Montefiori DC; LaBranche CC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Landucci G; Forthal DN; Seaman MS; Hawkins N; Self SG; Sato A; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Francis J; Galmin L; Ding S; Heeney JL; Pantaleo G; Wagner R
J Virol; 2016 Apr; 90(8):4133-4149. PubMed ID: 26865719
[TBL] [Abstract][Full Text] [Related]
17. Potent Anti-hepatitis C Virus (HCV) T Cell Immune Responses Induced in Mice Vaccinated with DNA-Launched RNA Replicons and Modified Vaccinia Virus Ankara-HCV.
Marín MQ; Pérez P; Ljungberg K; Sorzano CÓS; Gómez CE; Liljeström P; Esteban M; García-Arriaza J
J Virol; 2019 Apr; 93(7):. PubMed ID: 30674625
[TBL] [Abstract][Full Text] [Related]
18. Optimized Mucosal Modified Vaccinia Virus Ankara Prime/Soluble gp120 Boost HIV Vaccination Regimen Induces Antibody Responses Similar to Those of an Intramuscular Regimen.
Jones DI; Pollara JJ; Johnson-Weaver BT; LaBranche CC; Montefiori DC; Pickup DJ; Permar SR; Abraham SN; Maddaloni M; Pascual DW; Staats HF
J Virol; 2019 Jul; 93(14):. PubMed ID: 31068425
[TBL] [Abstract][Full Text] [Related]
19. TLR1/2 activation during heterologous prime-boost vaccination (DNA-MVA) enhances CD8+ T Cell responses providing protection against Leishmania (Viannia).
Jayakumar A; Castilho TM; Park E; Goldsmith-Pestana K; Blackwell JM; McMahon-Pratt D
PLoS Negl Trop Dis; 2011 Jun; 5(6):e1204. PubMed ID: 21695103
[TBL] [Abstract][Full Text] [Related]
20. Heterologous prime-boost: an important candidate immunization strategy against Tembusu virus.
Pan Y; Jia R; Li J; Wang M; Chen S; Liu M; Zhu D; Zhao X; Wu Y; Yang Q; Yin Z; Jing B; Huang J; Zhang S; Zhang L; Liu Y; Yu Y; Tian B; Pan L; Rehman MU; Cheng A
Virol J; 2020 May; 17(1):67. PubMed ID: 32398028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]